Sign in with Google. Opens in new tab
bearish
Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?
765 Views17 Jul 2019 04:58
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »Top Unpaywalled Insights
More »- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization13 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap11 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation22 Aug 2019
- Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio30 Jan 2019
- CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)25 Jan 2019
x